Caitong International Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Caitong International Asset Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$194K	Buy	3,330 +2,105	+172%	+$97K	0.04%	392
2025 Q4	$54.9K	Buy	+1,225	New	+$51.4K	0.01%	663
2025 Q3	–	Sell	-104	Closed	-$3.25K	–	2586
2025 Q2	$3.25K	Sell	104 -801	-89%	-$26.1K	﹤0.01%	1203
2025 Q1	$30.4K	Buy	+905	New	+$34.4K	0.02%	662

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Caitong International Asset Management's XENE Position: Q1 2026 in Review

Caitong International Asset Management increased its Xenon Pharmaceuticals (XENE) stake by 172% in Q1 2026, buying an estimated $97K and bringing the position to 3,330 shares worth $194K. The position accounts for 0.04% of the portfolio, ranked #392.

Caitong International Asset Management first reported a position in XENE in Q1 2025 and has held it in 4 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Caitong International Asset Management held 3,330 shares of Xenon Pharmaceuticals worth $194K as of Q1 2026.
Caitong International Asset Management bought 2,105 Xenon Pharmaceuticals shares in Q1 2026, an estimated $97K.
Xenon Pharmaceuticals made up 0.04% of Caitong International Asset Management's portfolio in Q1 2026, its #392 holding.
Caitong International Asset Management first reported a position in Xenon Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.